Ligand Pharmaceuticals (NASDAQ:LGND) stock surged 6.32% in intraday trading on Thursday after reporting better-than-expected fourth quarter 2024 earnings and providing an optimistic outlook for 2025.
For the fourth quarter, Ligand posted adjusted earnings per share of $1.27, beating the consensus analyst estimate of $1.19. Total revenue of $42.81 million also exceeded expectations of $39.02 million. The strong quarterly results were driven by a 52.35% year-over-year increase in sales.
Looking ahead, Ligand forecasts full-year 2025 adjusted EPS of $6.00 to $6.25 on projected revenue between $180 million and $200 million. Analysts were expecting EPS of $6.07 on revenue of $187.1 million, so the company's guidance came in largely ahead of estimates.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。